問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Endocrinology

Taipei Chang Gung Medical Foundation

Division of Endocrinology

更新時間：2025-12-16

謝勝湖Hsieh, Hsieh
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • ma1697@cgmh.org.tw

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝勝湖

List

16Cases

2006-08-01 - 2008-02-01

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-08-01 - 2010-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-07-01 - 2011-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2005-12-01 - 2006-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2010-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated1Sites

Study ended13Sites

2013-03-01 - 2015-07-31

Phase III

A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    MK-3102

Participate Sites
16Sites

Terminated16Sites

2017-08-01 - 2019-01-31

Phase III

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes PRONTO-T2D

  • Condition/Disease

    Type 2 Diabetes

  • Test Drug

    LY900014

Participate Sites
5Sites

Terminated5Sites

2017-08-01 - 2020-05-31

Phase III

Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes PRONTO-T1D.

  • Condition/Disease

    Type 1 Diabetes Mellitus

  • Test Drug

    LY900014

Participate Sites
6Sites

Terminated6Sites

歐弘毅
National Taiwan University Hospital

Division of Endocrinology

2014-12-01 - 2016-07-31

Phase III

Prospective, randomized, open, and comparative long-acting basal insulin analogue LY2963016 and LANTUS® (LANTUS®) in adults with type 2 diabetes: ELEMENT 5 trial.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2963016

Participate Sites
7Sites

Terminated7Sites

2013-12-01 - 2015-09-30

Phase III

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Patients with Type 2 Diabetes Mellitus: The ELEMENT 4 Study

  • Condition/Disease

    Type II diabetes

  • Test Drug

    Insulin Basal Analog V (LY2963016)

Participate Sites
9Sites

Terminated9Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB